and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC). These results were presented ...

and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC). These results were presented ...

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Individual results/experiences may vary. He is an expert when it comes to a challenging type of lung cancer. It's called ROS1+ non-small cell lung cancer (NSCLC), and it's known for being aggressive ...

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer ...

The Empowering Voices: Knowledge and Decision-Making Among People Impacted by Lung Cancer in Europe report, conducted by Lung Cancer Europe (LuCE) with the support of 40 member organisations, features ...

positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on to develop brain mets. Why is this? Doctors aren’t sure.

Non-small-cell lung cancer (NSCLC) is the most common form of ... People with a mutation in genes such as EGFR, KRAS, ALK, ROS1, BRAF, RET, or MET may be able to use targeted cancer drugs to ...

Priority Review designation underscores the significant advancement taletrectinib may offer patients with ROS1+ NSCLC, for which there remains a high unmet need for new treatment options.

The final EC decision is expected in January 2025. “Patients in the EU with ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors face a great unmet need for new therapies that ...